Drug intelligence / Profile preview

nitronazine

Development stage: Unknown
Lead developer: Guangzhou Magpie Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Nitronazine (MN-08) is a small molecule nitrone derivative being developed by Guangzhou Magpie Pharmaceutical for the treatment of diabetic kidney disease (DKD) and ischemic stroke. Chemically, it is a hybrid molecule combining the structure of tetramethylpyrazine (TMP), an active component of the herb Ligusticum wallichii, with a nitrone moiety. This design allows it to function as a potent free radical scavenger and antioxidant. Nitronazine aims to mitigate oxidative stress and inflammatory damage, which are key drivers in the progression of diabetic nephropathy and neuronal injury following a stroke. It has been shown to activate the Nrf2 signaling pathway and inhibit the NLRP3 inflammasome. The drug is currently in Phase II clinical development in China for both DKD and acute ischemic stroke.

Other names: 硝酮嗪

Targets

NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)ROS/ONOO- (Reactive oxygen species and peroxynitrite)

Beyond the preview

Go deeper on nitronazine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on nitronazine.

Explore the full profile